Login to Your Account



FDA Panel Backs Acorda MS Drug; Post-OK Trials Only

By Donna Young


Thursday, October 15, 2009
COLLEGE PARK, Md. — An FDA panel Wednesday voted 12 to 1 that Acorda Therapeutics Inc.'s Phase III trials provided substantial evidence that fampridine sustained-release was effective in improving the walking ability in patients with multiple sclerosis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription